Ginkgo Bioworks Holdings, Inc. (DNA) Financial Statements
Ginkgo Bioworks Holdings, Inc. (DNA) reported trailing twelve-month revenue of $111.9M (down 51.5% year on year) and net income of -$290.8M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$174.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DNAGinkgo Bioworks Holdings, Inc.Follow DNA — free
—
Price chart with a free account
- Market cap
- 672.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 0.31 | 0.48 | 0.25 | 0.23 | 0.17 | 0.11 | |
| Gross profit | 0.18 | 0.27 | 0.20 | 0.18 | 0.12 | — | |
| Research & development | 1.15 | 1.05 | 0.58 | 0.42 | 0.24 | 0.22 | |
| Operating income | -1.83 | -2.21 | -0.86 | -0.56 | -0.32 | -0.29 | |
| Pre-tax income | -1.84 | -2.12 | -0.89 | -0.55 | -0.31 | -0.30 | |
| Income tax | -0.00 | -0.02 | -0.00 | -0.00 | -0.00 | -0.00 | |
| Net income | -1.83 | -2.10 | -0.89 | -0.55 | -0.31 | -0.29 | |
| Diluted EPS ($) | -1.39 | -50.20 | -18.37 | -10.54 | -5.64 | -5.65 | |
| Diluted shares (bn) | 1.360 | 0.042 | 0.049 | 0.052 | 0.055 | — |
USD billions · SEC XBRL
Ginkgo Bioworks Holdings, Inc. — questions
- What is Ginkgo Bioworks Holdings, Inc.'s revenue?
- $111.9M over the twelve months to 2026-06-30, down 51.5% year on year, from its 10-Q and 10-K filings.
- What is Ginkgo Bioworks Holdings, Inc.'s net income?
- -$290.8M over the twelve months to 2026-06-30.
- What is Ginkgo Bioworks Holdings, Inc.'s free cash flow?
- -$174.8M over the twelve months to 2026-06-30.
- What are Ginkgo Bioworks Holdings, Inc.'s diluted earnings per share?
- $-5.65 over the twelve months to 2025-12-31.
Every figure on this page comes from Ginkgo Bioworks Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.